COMP <GO>
KRMN vs TMO // REVENUE GROWTH (YOY)
Karman Holdings Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: KRMN 4
— TMO 11
▲ REVENUE GROWTH (YOY) LEADER: KRMN
LAST: $39.95 (-4.17%) • MKT CAP: $5.53B
revenue-growth
36.60%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
revenue-growth
3.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRMN VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRMN | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 40.30% | 41.00% | -0.70 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.80% | 9.30% | -0.50 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 64.2x | 30.4x | +33.80 | TMO | /valuation <GO> |
| Free Cash Flow Yield | -0.77% | 2.40% | -3.17 | TMO | /fcf-yield <GO> |
| Operating Margin | 15.50% | 17.40% | -1.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 15.10% | -11.40 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 36.60% | 3.90% | +32.70 | KRMN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.47 | 4.50 | +0.97 | KRMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.70% | +0.10 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.2 | 59.1 | +2.08 | KRMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.94 | +0.02 | KRMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 36.3x | +103.70 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.53B | $262.22B | -$256.69B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRMN REV | TMO REV | KRMN GROSS % | TMO GROSS % | KRMN FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $471.5M | $44.56B | 40.3% | 44.0% | -$42.5M | $6.29B |
| FY 2024 | $345.3M | $42.88B | 38.3% | 44.0% | $11.4M | $7.27B |
| FY 2023 | $280.7M | $42.86B | 44.0% | 44.0% | $7.7M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRMN // BETA 0.96
TMO // BETA 0.94